{"groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"FG000","title":"Crizotinib"},{"description":"Pemetrexed 500 mg per square meter (mg/m\\^2) intravenous infusion over 10 minutes or docetaxel 75 mg/m\\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"FG001","title":"Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"115"},{"groupId":"FG001","numSubjects":"24"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"144"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"173"},{"groupId":"FG001","numSubjects":"174"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"172"},{"groupId":"FG001","numSubjects":"171"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"4"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"133"},{"groupId":"FG001","numSubjects":"170"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}